WSTWest Pharmaceutical Services

Health care · Medical Instruments · NYSE

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. 10-K, Item 1

Employees: 10,800
Headquarters: Exton, PA
CEO: Eric M. Green
Next results: around Feb 11, 2027

Compare with peers → Embed

The numbers WST said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 7 range targets with a reported result: 6 came in above the last range given, 1 within it, 0 below it.

Target	What the company said	Reported	Result
Capital expenditures Fiscal 2026	Given $250.00M to $275.00M release 2026-02-12 Lowered $215.00M to $220.00M release 2026-10-29	–	Not reported yet
The company's words Full-year 2026 capital expenditures are expected to be in the range of $250 million to $275 million. release 2026-02-12 Full-year 2026 capital spending guidance is updated to a range of $215 million to $220 million, down from the prior range of $250 million to $275 million. release 2026-10-29
Diluted EPS (company-defined) Fiscal 2026	Given $7.85 to $8.20 release 2026-02-12 Raised $8.40 to $8.75 release 2026-04-23 Raised $8.85 to $9.05 release 2026-07-23 Raised $9.38 to $9.48 release 2026-10-29	–	No standard number
The company's words Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20, representing growth of 7.7% to 12.5%. release 2026-02-12 Outlook for Full-Year and Second Quarter 2026 … Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up f rom $3.215 billion to $3.275 billion and full year 2026 adjusted-diluted EPS guidan ce increased to a range of $8.40 to $8.75 , up from $7.85 to $8.20. release 2026-04-23 Full-year 2026 adjusted-diluted EPS guidance increased to a range of $8.85 to $9.05. release 2026-07-23 Full-year 2026 adjusted-diluted EPS guidance increased to a range of $9.38 to $9.48, up from the previous range of $8.85 to $9.05. release 2026-10-29
Revenue Fiscal 2026	Given $3.21B to $3.27B release 2026-02-12 Raised $3.29B to $3.35B release 2026-04-23 Raised $3.35B to $3.38B release 2026-07-23 Raised $3.41B to $3.42B release 2026-10-29	–	Not reported yet
The company's words Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. release 2026-02-12 Full-year 2026 net sales guidance increased to a range of $3.295 billion to $3.350 billion, up f rom $3.215 billion to $3.275 billion and full year 2026 adjusted-diluted EPS guidan ce increased to a range of $8.40 to $8.75 , up from $7.85 to $8.20. release 2026-04-23 The Company is increasing its full-year 2026 net sales guidance range to $3.345 billion to $3.380 billion, up from $3.295 billion to $3.350 billion. release 2026-07-23 Full-year 2026 net sales guidance increased to a range of $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion. release 2026-10-29
Diluted EPS (company-defined) Q3 of fiscal 2026	Given $2.14 to $2.24 release 2026-07-23	–	No standard number
The company's words Third-quarter 2026 adjusted-diluted EPS guidance is expected to be in the range of $2.14 to $2.24. release 2026-07-23
Revenue Q3 of fiscal 2026	Given $820.00M to $835.00M release 2026-07-23	$874.50M 10-Q filed 2026-10-29	Above the range
The company's words The Company is introducing its third-quarter 2026 net sales guidance range of $820 million to $835 million. release 2026-07-23
Diluted EPS (company-defined) Q2 of fiscal 2026	Given $2.05 to $2.12 release 2026-04-23	–	No standard number
The company's words The Company is introducing its second-quarter 2026 adjusted-diluted EPS guidance range of $2.05 to $2.12, up 11.4% to 15.2%. release 2026-04-23
Revenue Q2 of fiscal 2026	Given $830.00M to $850.00M release 2026-04-23	$872.30M 10-Q filed 2026-07-23	Above the range
The company's words The Company is introducing its second-quarter 2026 net sales guidance range of $830 million to $850 million. release 2026-04-23
Diluted EPS (company-defined) Q1 of fiscal 2026	Given $1.65 to $1.70 release 2026-02-12	–	No standard number
The company's words Introducing Full-Year and First-Quarter 2026 Financial Guidance … First-quarter adjusted-diluted EPS is expected to be in the range of $1.65 to $1.70, up 13.0% to 16.4%. 2 release 2026-02-12
Capital expenditures Fiscal 2025 (ended 2025-12-31)	Given $275.00M release 2025-02-13 Kept $275.00M release 2025-04-24 Kept $275.00M release 2025-07-24 Kept $275.00M release 2025-10-23	$285.90M 10-K filed 2026-02-17	Above the range
The company's words Full-year 2025 capital spending is expected to be $275 million. release 2025-02-13 Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million. release 2025-04-24 Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million. release 2025-07-24 Full-Year 2025 Financial Guidance … Capital spending guidance is unchanged at $275 million. release 2025-10-23
Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $6.00 to $6.20 release 2025-02-13 Raised $6.15 to $6.35 release 2025-04-24 Raised $6.65 to $6.85 release 2025-07-24 Raised $7.06 to $7.11 release 2025-10-23	–	No standard number
The company's words For full-year 2025, the Company anticipates net sales in a range of $2.875 billion to $2.905 billion and adjusted-diluted EPS in the range of $6.00 to $6.20. release 2025-02-13 The Company is increasing its full year 2025 adjusted-diluted EPS guidance range to $6.15 to $6.35, up from the previous range of $6.00 to $6.20, which incorporates an estimate of $20 to $25 million in tariff costs. release 2025-04-24 Updates full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35. release 2025-07-24 Full-year 2025 adjusted-diluted EPS guidance increased to a range of $7.06 to $7.11 , up from $6.65 to $6.85. release 2025-10-23
Revenue Fiscal 2025 (ended 2025-12-31)	Given $2.88B to $2.90B release 2025-02-13 Raised $2.94B to $2.98B release 2025-04-24 Raised $3.04B to $3.06B release 2025-07-24 Raised $3.06B to $3.07B release 2025-10-23	$3.07B 10-K filed 2026-02-17	Above the range
The company's words For full-year 2025, the Company anticipates net sales in a range of $2.875 billion to $2.905 billion and adjusted-diluted EPS in the range of $6.00 to $6.20. release 2025-02-13 The Company is increasing its full year 2025 net sales guidance range to $2.945 billion to $2.975 billion, up from previous guidance of $2.875 billion to $2.905 billion. release 2025-04-24 Updates full-year 2025 net sales guidan ce range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion. release 2025-07-24 Full-year 2025 net sales guidan ce increased to a range of $3.060 billion to $3.070 billion, up from $3.040 billion to $3.060 billion. release 2025-10-23
Diluted EPS (company-defined) Q4 of fiscal 2025	Given $1.81 to $1.86 release 2025-10-23	–	No standard number
The company's words The Company is introducing its fourth-quarter 2025 adjusted-diluted EPS guidance range of $1.81 to $1.86. release 2025-10-23
Revenue Q4 of fiscal 2025	Given $790.00M to $800.00M release 2025-10-23	$805.00M 10-K filed 2026-02-17	Above the range
The company's words The Company is introducing its fourth-quarter 2025 net sales guidance range of $790 million to $800 million. release 2025-10-23
Capital expenditures Fiscal 2024 (ended 2024-12-31)	Given $350.00M release 2024-02-15 Kept $350.00M release 2024-04-25 Raised $375.00M release 2024-07-25 Kept $375.00M release 2024-10-24	$377.00M 10-K filed 2025-02-18	Above the range
The company's words Full-year 2024 capital spending is expected to be $350 million. release 2024-02-15 Full-year 2024 capital spending guidance is unchanged and is expected to be $350 million. release 2024-04-25 Full-year 2024 capital spending is expected to be $375 million, an increase from the previous estimate of $350 million. release 2024-07-25 Full-year 2024 capital spending guidance is unchanged and is expected to be $375 million. release 2024-10-24
Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $7.50 to $7.75 release 2024-02-15 Raised $7.63 to $7.88 release 2024-04-25 Lowered $6.35 to $6.65 release 2024-07-25 Raised $6.55 to $6.75 release 2024-10-24	–	No standard number
The company's words The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75. release 2024-02-15 The Company is raising full-year 2024 adjusted-diluted EPS guidance to a new range of $7.63 to $7.88, compared to a prior range of $7.50 to $7.75. release 2024-04-25 The Company is updating full-year 2024 adjusted-diluted EPS guidance to a range of $6.35 to $6.65, compared to a prior range of $7.63 to $7.88. release 2024-07-25 The Company increased its full-year 2024 adjusted-diluted EPS guidance range to $6.55 to $6.75, up from its previous guidance range of $6.35 to $6.65. release 2024-10-24
Revenue Fiscal 2024 (ended 2024-12-31)	Given $3.00B to $3.02B release 2024-02-15 Kept $3.00B to $3.02B release 2024-04-25 Lowered $2.87B to $2.90B release 2024-07-25 Raised $2.88B to $2.90B release 2024-10-24	$2.89B 10-K filed 2025-02-18	Within the range
The company's words The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75. release 2024-02-15 The Company is reaffirming full-year 2024 net sales guidance in a range of $3.000 billion to $3.025 billion. release 2024-04-25 The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compared to a prior range of $3.000 billion to $3.025 billion. release 2024-07-25 As a result of favorable currency movements, the Company increased its full year 2024 net sales guidance range to $2.875 billion to $2.905 billion, up from its previous guidance range of $2.870 billion to $2.900 billion. release 2024-10-24

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-15), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on WST in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/WST/export.csv") into a cell.